RecruitingNot ApplicableNCT06155188
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
A Novel Post-transplant Regimen of PT/FLU+CY for Selectively Promoting Unrelated Cord Blood Engraftment in Haploidentical-cord Transplantation in Childhood Leukemia: a Single-arm, Multi-center Trial
Sponsor
Nanfang Hospital, Southern Medical University
Enrollment
60 participants
Start Date
Sep 29, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
To determine if the novel regimen of PT/FLU+CY promotes cord blood engraftment in children's leukemia HSCT cohort
Eligibility
Min Age: 1 MonthMax Age: 18 Years
Inclusion Criteria1
- children acute leukemia
Exclusion Criteria1
- MODS
Interventions
PROCEDUREapplying of FLU+CY post-HSCT
The conditioning regimen (PT-Cy/Flu group) consisted of fludarabine (40mg/m2, d-5 to d-3 and d+3, d+4), busulfan (100mg/m2, d-6 to d-3), haplo-PBSC (d0), PTCy (50mg/kg, d+3, d+4) and UCB (d+6).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06155188
Related Trials
CIML NK Cells With Venetoclax for AML
NCT061528092 locations
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
NCT052379863 locations
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
NCT068904941 location
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
NCT068562261 location
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
NCT072946771 location